A Case of Myeloproliferative Neoplasm with BCR-FGFR1 Rearrangement: Favorable Outcome after Haploidentical Allogeneic Transplantation

Table 1

Characteristics of 12 patients with BCR-FGFR1 rearrangement treated with allo-HSTCT.

Case	Reference	Age (years)/sex	Diagnosis	Donor source	Response
1	Present report	65/M	MPN	Haploidentical HSCT	CCyR
2	Konishi et al., 2018 [8]	48/M	B-ALL/MPN	Mismatched unrelated, BM	CCyR
3	Montenegro et al., 2017 [3]	41/F	B-ALL/MPN	NR	Residual disease
4	Wang et al., 2016 [9]	56/F	B-ALL/MPN	Matched unrelated AHSCT	Remission for 5 months after AHSCT
5	Landberg et al., 2017 [10]	21/M	MPN	Mismatched unrelated AHSCT	Remission for 4 years after AHSCT
6	Khodadoust et al., 2015 [11]	47/M	Trilineage mixed-phenotype AL	Matched sibling allogeneic HSCT	Residual disease
7	Shimanuki et al., 2013 [12]	58/F	AL with dysplasia	Matched sibling allogeneic HSCT	Residual disease and subsequent relapse
8	Morishige et al., 2013 [7]	50/M	Trilineage AL/lymphoma	Cord blood	Remission for 2 years after AHSCT
9	Dolan et al., 2012 [6]	8/M	MDS/MPN	Unrelated AHSCT	Remission for 4.5 years after AHSCT
10	Haslam et al., 2012 [13]	21/M	B-ALL/MPN	Mismatched, unrelated AHSCT	Residual disease
11	Kim et al., 2011 [14]	59/M	Myeloid, T cell	AHSCT	CCyR
12	Patnaik et al., 2010 [15]	57/F	MPN	AHSCT	Remission for 42 months after AHSCT

Abbreviations: M: male; F: female; MPN: myeloproiferative neoplasm; B-ALL: B-cell acute lymphoblastic leukaemia; CCyR: complete cytogenetic response; AL: acute leukaemia; MDS: myelodysplastic syndrome; AHSCT: allogeneic hematopoietic stem-cell transplantation; BM: bone marrow; NR: Not reported.